Developer docs
API playgroundTry for free, no card

Search company profiles

Marea Therapeutics

Full company profile

uuid0000d2s

Namestring
Marea Therapeutics
Legal namestring
Marea Therapeutics, Inc.
Websiteurl
mareatx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Marea Therapeutics, Inc. is a clinical-stage biotechnology company headquartered at 131 Oyster Point Boulevard in South San Francisco, California, developing first-in-class therapies for cardioendocrine diseases. The company was founded with backing from Third Rock Ventures (which co-developed the concept via Ethan Weiss's entrepreneur-in-residence engagement) and is led by CEO Josh Lehrer, M.D., former CEO of Graphite Bio and Chief Medical Officer of Global Blood Therapeutics. Marea's discovery engine is built on large-scale human genetic data combined with adipocyte biology to identify genetically validated targets, with the goal of treating underlying disease biology rather than symptoms. Its lead programs are MAR001, a first-in-class anti-ANGPTL4 monoclonal antibody in Phase 2b development for severe hypertriglyceridemia (sHTG) and atherosclerotic cardiovascular disease (ASCVD); MAR002, a half-life-extended allosteric growth hormone receptor antagonist monoclonal antibody for acromegaly, which produced positive Phase 1 data in January 2026 demonstrating 52% peak IGF-1 suppression and durability supportive of biweekly to monthly dosing; and MAR003, an undisclosed ASCVD target in discovery. The company is also advancing a half-life-extended MAR001 (MAR001-HLE) toward an IND filing in 2026 and an adipose-targeted ANGPTL4 siRNA preclinical program.

Marea's business model is presently pre-revenue. As a clinical-stage biotech, it generates no product sales and funds operations through venture capital. The company filed an SEC Form D in June 2024 covering approximately $190 million in aggregate securities, including a $190 million Series A financing (with a concurrent ~$65 million Third Rock Ventures tranche) led by Forbion, Perceptive Advisors, Sofinnova Investments, and venBio Partners, alongside Alpha Wave, Omega Funds, Surveyor, and Third Rock Ventures. Future revenue mechanics are expected to derive from pharmaceutical commercialization upon regulatory approval, supplemented by potential out-licensing or partnership transactions, with traditional pharmaceutical distribution and direct sales channels planned. Marea's go-to-market strategy today is enterprise field sales in nature — building scientific credibility, clinical data assets, and pharmaceutical partnerships through presentations at medical conferences (e.g., ENDO 2026) and press releases, ahead of any commercial launch. The company operates a wholly-owned Australian subsidiary (Marea Therapeutics Pty Ltd) coordinating Australian clinical activities, and serves an eventual addressable market of patients with cardioendocrine diseases including severe hypertriglyceridemia, ASCVD, and acromegaly (~30,000+ U.S. acromegaly patients).

Short descriptiontext

Marea Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody and siRNA therapies for cardioendocrine diseases, including severe hypertriglyceridemia, ASCVD, and acromegaly, serving patients with limited effective treatment options.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardioendocrine therapeutics, monoclonal antibody development, clinical-stage biotechnology, ANGPTL4 inhibition, acromegaly treatment
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, Marea Therapeutics is developing novel therapeutics with the goal of commercializing pharmaceutical products for cardioendocrine diseases. The company has not yet generated revenue from product sales. MAR001 is in Phase 2b for severe hypertriglyceridemia and ASCVD, and MAR002 is advancing toward Phase 2/3 for acromegaly.

mareatx.com
2Securities Offering / Funding
TypeLicensing Royalties
Description

The company raised approximately $160 million through a Form D SEC filing for exempt securities offering, with around $65 million already sold as of June 2024.

sec.gov
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class monoclonal antibody and siRNA therapeutics that target genetically validated drivers of cardioendocrine diseases, including severe hypertriglyceridemia, atherosclerotic cardiovascular disease, and acromegaly. Its lead candidates are MAR001 (an anti-ANGPTL4 monoclonal antibody in Phase 2b), MAR002 (a half-life-extended allosteric growth hormone receptor antagonist antibody for acromegaly), and MAR003 (an undisclosed ASCVD program in discovery).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • MAR002 achieved 52% peak IGF-1 suppression with greater than 45% suppression lasting 43 days (vs. 48% peak and greater than 45% lasting only 5 days for current standard of care)
+3 more records
Product overview1 text field

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies targeting cardioendocrine diseases. The company's core portfolio includes three product candidates: MAR001 (ANGPTL4 inhibitor, Phase 2) for severe hypertriglyceridemia and ASCVD; MAR002 (GHR antagonist, IND-Enabling) for acromegaly; and MAR003 (undisclosed target, discovery stage) for ASCVD. The company is also advancing MAR001-HLE, a half-life-extended formulation of MAR001 designed for monthly dosing, and an ANGPTL4 siRNA preclinical program targeting adipose tissue.

Product and service5 records
1MAR001
CategoryCore product / clinical-stage monoclonal antibody therapeutic
Description

A first-in-class monoclonal antibody targeting ANGPTL4 (angiopoietin-like 4 protein) designed to block the activity of this genetically validated driver of remnant cholesterol and atherosclerotic cardiovascular disease risk, leading to augmented hydrolysis of triglyceride-rich lipoproteins and reductions in triglycerides and remnant cholesterol. Currently in Phase 2b for severe hypertriglyceridemia and ASCVD.

2MAR002
CategoryCore product / clinical-stage monoclonal antibody therapeutic
Description

A potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. Designed for infrequent subcutaneous dose administration, potentially enabling dosing as infrequently as once every two weeks compared to daily injections required by the current standard of care.

3MAR003
CategoryCore product / discovery-stage therapeutic program
Description

An undisclosed discovery-stage program targeting a genetically validated driver of atherosclerotic cardiovascular disease (ASCVD).

4MAR001-HLE
CategorySub-product / next-generation monoclonal antibody formulation
Description

A half-life-extended version of MAR001 incorporating Fc modifications designed to improve pharmacokinetics, enable monthly low-volume subcutaneous dosing, and significantly reduce cost of goods. Advancing toward Phase 3 readiness with IND filing anticipated in 2026.

5ANGPTL4 siRNA Program
CategoryPreclinical program / RNA-based therapeutic
Description

A preclinical small interfering RNA (siRNA) program targeting ANGPTL4 with a differentiated, adipose-tissue-focused approach, intended to complement Marea's monoclonal antibody pipeline with a next-generation modality.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Crinetics is a clinical-stage endocrine-focused biotech whose lead asset paltusotine (oral nonpeptide somatostatin agonist) is in Phase 3 for acromegaly — making it the most direct head-to-head competitor to MAR002 in the same indication with a similar patient population.

TypeDirect peer
Description

Camurus is developing CAM2029, a subcutaneous weekly octreotide formulation in Phase 3 for acromegaly, directly competing with MAR002 on dosing-convenience differentiation within the same rare endocrine indication.

TypeDirect peer
Description

Madrigal developed resmetirom (Rezdiffra) for MASH with cardiovascular comorbidities, and is the closest peer in the cardioendocrine/metabolic liver-heart intersection that Marea also targets with ANGPTL4 and GHR programs.

TypeDirect peer
Description

NewAmsterdam is a late-stage cardiometabolic biotech developing obicetrapib (CETP inhibitor) for dyslipidemia and ASCVD risk reduction — directly comparable to Marea's MAR001 program in mechanism, indication, and stage of cardiovascular lipid management development.

TypeBroad incumbent
Description

Alnylam is the established leader in siRNA therapeutics (Onpattro, Givlaari, Oxlumo, Leqvio via Novartis partnership) and is the most relevant platform peer to Marea's emerging adipose-targeted ANGPTL4 siRNA program, defining the competitive and partnering landscape for RNAi-based cardiometabolic medicines.

TypeBroad incumbent
Description

Ionis is a leader in RNA-targeted therapeutics (antisense oligonucleotides) with multiple cardiometabolic programs (e.g., olezarsen for familial chylomicronemia, plozasiran via Arrowhead collaboration), making it a direct platform and indication peer to both MAR001 and the siRNA program.

TypeBroad incumbent
Description

BridgeBio develops genetic-disease medicines including cardiovascular programs (e.g., acoramidis for transthyretin amyloid cardiomyopathy, approved as Attruby). Its genetically validated target approach parallels Marea's discovery strategy and its late-stage cardiovascular experience makes it a relevant comparator.

TypeEmerging player
Description

Verve is a clinical-stage genetic medicines company developing in vivo gene editing for cardiovascular disease (VERVE-101, VERVE-102 for PCSK9). It shares Marea's genetically validated cardiovascular target strategy but uses a different modality (base editing vs. monoclonal antibody/siRNA).

TypeEmerging player
Description

Lexicon is developing sotagliflozin (SGLT1/2 inhibitor) for heart failure and other cardioendocrine indications. While smaller and at a different stage, its focus on cardioendocrine mechanisms and cardiovascular outcomes development makes it a relevant emerging peer.

TypeEmerging player
Description

Soleno develops diazoxide choline extended-release (DCCR) for Prader-Willi syndrome and has explored related rare endocrine and metabolic indications. Its late-stage rare endocrine focus and small-cap clinical biotech profile make it a comparable peer for MAR002's rare-disease positioning strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marea Therapeutics

Biopharmaceuticalsmareatx.com

Marea Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody and siRNA therapies for cardioendocrine diseases, including severe hypertriglyceridemia, ASCVD, and acromegaly, serving patients with limited effective treatment options.

What Marea Therapeutics does

Marea Therapeutics, Inc. is a clinical-stage biotechnology company headquartered at 131 Oyster Point Boulevard in South San Francisco, California, developing first-in-class therapies for cardioendocrine diseases. The company was founded with backing from Third Rock Ventures (which co-developed the concept via Ethan Weiss's entrepreneur-in-residence engagement) and is led by CEO Josh Lehrer, M.D., former CEO of Graphite Bio and Chief Medical Officer of Global Blood Therapeutics. Marea's discovery engine is built on large-scale human genetic data combined with adipocyte biology to identify genetically validated targets, with the goal of treating underlying disease biology rather than symptoms. Its lead programs are MAR001, a first-in-class anti-ANGPTL4 monoclonal antibody in Phase 2b development for severe hypertriglyceridemia (sHTG) and atherosclerotic cardiovascular disease (ASCVD); MAR002, a half-life-extended allosteric growth hormone receptor antagonist monoclonal antibody for acromegaly, which produced positive Phase 1 data in January 2026 demonstrating 52% peak IGF-1 suppression and durability supportive of biweekly to monthly dosing; and MAR003, an undisclosed ASCVD target in discovery. The company is also advancing a half-life-extended MAR001 (MAR001-HLE) toward an IND filing in 2026 and an adipose-targeted ANGPTL4 siRNA preclinical program.

Marea's business model is presently pre-revenue. As a clinical-stage biotech, it generates no product sales and funds operations through venture capital. The company filed an SEC Form D in June 2024 covering approximately $190 million in aggregate securities, including a $190 million Series A financing (with a concurrent ~$65 million Third Rock Ventures tranche) led by Forbion, Perceptive Advisors, Sofinnova Investments, and venBio Partners, alongside Alpha Wave, Omega Funds, Surveyor, and Third Rock Ventures. Future revenue mechanics are expected to derive from pharmaceutical commercialization upon regulatory approval, supplemented by potential out-licensing or partnership transactions, with traditional pharmaceutical distribution and direct sales channels planned. Marea's go-to-market strategy today is enterprise field sales in nature — building scientific credibility, clinical data assets, and pharmaceutical partnerships through presentations at medical conferences (e.g., ENDO 2026) and press releases, ahead of any commercial launch. The company operates a wholly-owned Australian subsidiary (Marea Therapeutics Pty Ltd) coordinating Australian clinical activities, and serves an eventual addressable market of patients with cardioendocrine diseases including severe hypertriglyceridemia, ASCVD, and acromegaly (~30,000+ U.S. acromegaly patients).

Marea Therapeutics firmographics

Firmographics
Name
Marea Therapeutics
Legal name
Marea Therapeutics, Inc.
Website
https://mareatx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Marea Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody and siRNA therapies for cardioendocrine diseases, including severe hypertriglyceridemia, ASCVD, and acromegaly, serving patients with limited effective treatment options.
Ownership category
akta.pro rank

Where Marea Therapeutics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Marea Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Commercialization: As a clinical-stage biotechnology company, Marea Therapeutics is developing novel therapeutics with the goal of commercializing pharmaceutical products for cardioendocrine diseases. The company has not yet generated revenue from product sales. MAR001 is in Phase 2b for severe hypertriglyceridemia and ASCVD, and MAR002 is advancing toward Phase 2/3 for acromegaly.
  2. Securities Offering / Funding: The company raised approximately $160 million through a Form D SEC filing for exempt securities offering, with around $65 million already sold as of June 2024.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Marea Therapeutics product offering

Product offering

Core offering

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class monoclonal antibody and siRNA therapeutics that target genetically validated drivers of cardioendocrine diseases, including severe hypertriglyceridemia, atherosclerotic cardiovascular disease, and acromegaly. Its lead candidates are MAR001 (an anti-ANGPTL4 monoclonal antibody in Phase 2b), MAR002 (a half-life-extended allosteric growth hormone receptor antagonist antibody for acromegaly), and MAR003 (an undisclosed ASCVD program in discovery).

Product overview

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies targeting cardioendocrine diseases. The company's core portfolio includes three product candidates: MAR001 (ANGPTL4 inhibitor, Phase 2) for severe hypertriglyceridemia and ASCVD; MAR002 (GHR antagonist, IND-Enabling) for acromegaly; and MAR003 (undisclosed target, discovery stage) for ASCVD. The company is also advancing MAR001-HLE, a half-life-extended formulation of MAR001 designed for monthly dosing, and an ANGPTL4 siRNA preclinical program targeting adipose tissue.

Differentiator

Problem solved

Functional benefit

Products and services

  • MAR001 A first-in-class monoclonal antibody targeting ANGPTL4 (angiopoietin-like 4 protein) designed to block the activity of this genetically validated driver of remnant cholesterol and atherosclerotic cardiovascular disease risk, leading to augmented hydrolysis of triglyceride-rich lipoproteins and reductions in triglycerides and remnant cholesterol. Currently in Phase 2b for severe hypertriglyceridemia and ASCVD.
  • MAR002 A potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. Designed for infrequent subcutaneous dose administration, potentially enabling dosing as infrequently as once every two weeks compared to daily injections required by the current standard of care.
  • MAR003 An undisclosed discovery-stage program targeting a genetically validated driver of atherosclerotic cardiovascular disease (ASCVD).
  • MAR001-HLE A half-life-extended version of MAR001 incorporating Fc modifications designed to improve pharmacokinetics, enable monthly low-volume subcutaneous dosing, and significantly reduce cost of goods. Advancing toward Phase 3 readiness with IND filing anticipated in 2026.
  • ANGPTL4 siRNA Program A preclinical small interfering RNA (siRNA) program targeting ANGPTL4 with a differentiated, adipose-tissue-focused approach, intended to complement Marea's monoclonal antibody pipeline with a next-generation modality.

Quantifiable outcome

  • MAR002 achieved 52% peak IGF-1 suppression with greater than 45% suppression lasting 43 days (vs. 48% peak and greater than 45% lasting only 5 days for current standard of care)
  • +3 more outcomes

Companies that use Marea Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Marea Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Marea Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Marea Therapeutics competitors and assessment

Company assessment

Direct peers

  • Crinetics Pharmaceuticals: Crinetics is a clinical-stage endocrine-focused biotech whose lead asset paltusotine (oral nonpeptide somatostatin agonist) is in Phase 3 for acromegaly — making it the most direct head-to-head competitor to MAR002 in the same indication with a similar patient population.
  • Camurus: Camurus is developing CAM2029, a subcutaneous weekly octreotide formulation in Phase 3 for acromegaly, directly competing with MAR002 on dosing-convenience differentiation within the same rare endocrine indication.
  • Madrigal Pharmaceuticals: Madrigal developed resmetirom (Rezdiffra) for MASH with cardiovascular comorbidities, and is the closest peer in the cardioendocrine/metabolic liver-heart intersection that Marea also targets with ANGPTL4 and GHR programs.
  • NewAmsterdam Pharma: NewAmsterdam is a late-stage cardiometabolic biotech developing obicetrapib (CETP inhibitor) for dyslipidemia and ASCVD risk reduction — directly comparable to Marea's MAR001 program in mechanism, indication, and stage of cardiovascular lipid management development.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the established leader in siRNA therapeutics (Onpattro, Givlaari, Oxlumo, Leqvio via Novartis partnership) and is the most relevant platform peer to Marea's emerging adipose-targeted ANGPTL4 siRNA program, defining the competitive and partnering landscape for RNAi-based cardiometabolic medicines.
  • Ionis Pharmaceuticals: Ionis is a leader in RNA-targeted therapeutics (antisense oligonucleotides) with multiple cardiometabolic programs (e.g., olezarsen for familial chylomicronemia, plozasiran via Arrowhead collaboration), making it a direct platform and indication peer to both MAR001 and the siRNA program.
  • BridgeBio Pharma: BridgeBio develops genetic-disease medicines including cardiovascular programs (e.g., acoramidis for transthyretin amyloid cardiomyopathy, approved as Attruby). Its genetically validated target approach parallels Marea's discovery strategy and its late-stage cardiovascular experience makes it a relevant comparator.

Emerging players

  • Verve Therapeutics: Verve is a clinical-stage genetic medicines company developing in vivo gene editing for cardiovascular disease (VERVE-101, VERVE-102 for PCSK9). It shares Marea's genetically validated cardiovascular target strategy but uses a different modality (base editing vs. monoclonal antibody/siRNA).
  • Lexicon Pharmaceuticals: Lexicon is developing sotagliflozin (SGLT1/2 inhibitor) for heart failure and other cardioendocrine indications. While smaller and at a different stage, its focus on cardioendocrine mechanisms and cardiovascular outcomes development makes it a relevant emerging peer.
  • Soleno Therapeutics: Soleno develops diazoxide choline extended-release (DCCR) for Prader-Willi syndrome and has explored related rare endocrine and metabolic indications. Its late-stage rare endocrine focus and small-cap clinical biotech profile make it a comparable peer for MAR002's rare-disease positioning strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Marea Therapeutics social profiles

Digital presence

Marea Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marea Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Marea Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Marea Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marea Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marea Therapeutics

What does Marea Therapeutics do?

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class monoclonal antibody and siRNA therapeutics that target genetically validated drivers of cardioendocrine diseases, including severe hypertriglyceridemia, atherosclerotic cardiovascular disease, and acromegaly. Its lead candidates are MAR001 (an anti-ANGPTL4 monoclonal antibody in Phase 2b), MAR002 (a half-life-extended allosteric growth hormone receptor antagonist antibody for acromegaly), and MAR003 (an undisclosed ASCVD program in discovery).

Is Marea Therapeutics a public or private company?

Marea Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Marea Therapeutics founded?

Marea Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Marea Therapeutics based?

Marea Therapeutics is headquartered in San Francisco, United States, in the North America region.

How does Marea Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Development and Commercialization is the primary driver. The others are securities Offering / Funding.

Who are Marea Therapeutics's main competitors?

Direct peers on record are Crinetics Pharmaceuticals, Camurus, Madrigal Pharmaceuticals and NewAmsterdam Pharma. Broad incumbents are Alnylam Pharmaceuticals, Ionis Pharmaceuticals and BridgeBio Pharma. Emerging players are Verve Therapeutics, Lexicon Pharmaceuticals and Soleno Therapeutics.

Does Marea Therapeutics have an API?

No public API is recorded for Marea Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobalDataMarea Therapeutics’ MAR001 holds potential to reshape triglyceride-lowering landscape, says GlobalData – GlobalDataMarea Therapeutics' MAR001 achieved up to 57.2% triglyceride reduction and 40.8% remnant cholesterol reduction in a Phase IIb trial, but also raised LDL-C. The drug's novel ANGPTL4 inhibition offers differentiation from competing therapies, though longer-term safety data and clinical benefits are needed.Investing.comMarea Therapeutics at Jefferies Global Healthcare Conference: two shots at crowded marketsMarea Therapeutics presented its two-program strategy at Jefferies' healthcare conference, citing clinical data and a strengthened balance sheet. The company's financing extends its runway through mid-2028, covering major milestones for its severe hypertriglyceridemia and acromegaly programs. It plans to confirm early data in larger studies before phase III trials.YahooLisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trialMarea Therapeutics reported that its antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial showed sustained reductions and normal triglyceride levels in 51.7% of patients at the highest dose. Part B enrollment has begun, with MAR005 planned as the Phase 3 candidate.Endpoints NewsMarea’s triglyceride candidate could have an edge in diabetic patientsMarea Therapeutics' investigational lipid-lowering medicine has shown further promise in cutting triglycerides in patients with dangerously high levels of these fatty molecules in their blood. The company's CSO and CEO are pictured, but no specific trial results or data are disclosed.YahooMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of MedicineMarea Therapeutics announced that MAR001 met all objectives in Part A of the Phase 2b TYDAL-TIMI 78 trial, reducing triglycerides by up to 72.2% in participants with baseline levels ≥500 mg/dL. The data, presented at AHA 2026 and published in NEJM, showed no worsening of HbA1c, and Part B enrollment in severe hypertriglyceridemia has begun.Stock TitanMarea Therapeutics: 45.5% placebo-adjusted triglyceride cutMarea Therapeutics announced that MAR001 met all objectives in Part A of the Phase 2b TYDAL-TIMI 78 trial, reducing triglycerides by up to 72.2% from baseline in participants with levels ≥500 mg/dL. The drug showed no worsening of glycemic control, and Part B enrollment has begun in severe hypertriglyceridemia patients.FierceBiotechRecent Lisata prize Marea touts ‘exciting’ lipid disorder phase 2 win, mulls obesity potentialMarea Therapeutics, a Lisata subsidiary, reported phase 2b data showing its ANGPTL4 antibody MAR001 reduced triglycerides by 72.2% in patients with levels ≥500 mg/dL. Over half of 235 patients reached normal levels versus 3.4% on placebo. The company plans a phase 3 study for a half-life-extended version, MAR005.Business & FinancialMarea Therapeutics, A Subsidiary Of Lisata Therapeutics, To Participate In Upcoming November Investor ConferencesMarea Therapeutics, a subsidiary of Lisata, will present at three investor conferences in November, including Guggenheim Healthcare Innovation and Jefferies Global Healthcare. Its lead product candidate MAR001 is in Phase 2b for severe hypertriglyceridemia, with MAR002 advancing for acromegaly.Stock TitanLisata's Marea to Present at Two November ConferencesMarea Therapeutics, a subsidiary of Lisata, will present at three investor conferences in November, starting with the Guggenheim Healthcare Innovation Conference on November 10. The company's lead product candidate MAR001 is in Phase 2b for severe hypertriglyceridemia, with MAR002 advancing for acromegaly.